Answers are grounded in this paper and cite their sources.
Objective P53 negativity is a shared diagnostic feature of both some high-grade serous ovarian carcinoma (HGSOC) and cervical cancer, yet the underlying mechanisms remain poorly defined. This study aimed to elucidate the distinct pathogenic mechanisms and signaling dependencies that distinguish P53-negative HGSOC from P53-negative cervical cancer. Methods Hematoxylin and eosin (H&E) and P53 immunohistochemistry (IHC) were performed on archival HGSOC and cervical cancer cohorts. Clinical parameters were collected for P53-negative cases, followed by comprehensive molecular profiling using targeted next-generation sequencing (NGS). Differentially mutated genes were subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Results Patients with P53-negative HGSOC were significantly older (≥ 50 years: 81.25% vs. 50%, P < 0.05) and exhibited a five-fold higher mortality rate (25% vs. 5%) than the P53-negative cervical cancer cohort. Molecular profiling revealed that all 16 P53-negative HGSOC cases harbored deleterious TP53 mutations, whereas P53-negative cervical cancers showed wild-type TP53 but high mutation frequencies in PIK3CA (33.33%) and TERT (27.78%); notably, the P53-negative phenotype in cervical cancer was attributable to E6 oncoprotein-driven ubiquitin-mediated proteasomal degradation of wild-type P53 rather than to TP53 gene inactivation. Pathway analysis further distinguished these entities: P53-null HGSOC mutations preferentially enriched the PI3K/AKT/mTOR axis, whereas cervical cancer mutations converged on the MAPK/ERK pathway. Conclusion P53 negativity masks divergent oncogenic trajectories driven by fundamentally different mechanisms. In HGSOC, the P53-negative phenotype arises from intrinsic TP53 loss-of-function mutations, whereas in cervical cancer it predominantly reflects HPV E6-mediated post-translational degradation of wild-type P53 protein. Consequently, cervical carcinogenesis appears to rely on alternative pathway dysregulation (e.g., MAPK/ERK activation) independent of primary TP53 inactivation. These findings highlight the necessity of histology-specific, mechanism-driven therapeutic strategies that incorporate HPV status in P53-negative gynecological malignancies.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: